PremiumCompany AnnouncementsJourney Medical Reports 2024 Financial Results Fortress Biotech Inc (FBIO) Q4 Earnings Cheat Sheet Fortress Biotech, Partex enter collaboration for asset identification PremiumThe FlyCheckpoint Therapeutics jumps after deal to be acquired by Sun Pharma Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex Fortress, Cyprium announce FDA acceptance, priority review of NDA for CUTX-101 PremiumThe FlyFortress Biotech price target raised to $26 from $24 at H.C. Wainwright Fortress Biotech’s Q3 2024 Earnings and FDA Milestone Fortress Biotech Inc (FBIO) Q3 Earnings Cheat Sheet 
